Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

<strong>Background:</strong> In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kityo, C, Szubert, A, Siika, A, Heydermann, R, Bwakura-Dangarembizi, M, Lugemwa, A, Mwaringa, S, Griffiths, A, Nkanya, I, Kabahenda, S, Wachira, S, Musoro, G, Rajapakse, C, Etyang, T, Abach, J, Spyer, M, Wavamunno, P, Nyondo-Mipanda, L, Chidziva, E, Nathoo, K, Klein, N, Hakim, J, Gibb, D, Walker, A, Pett, S
Formato:	Journal article
Publicado:	Public Library of Science 2018

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

Ejemplares similares